Memel Biotech’s Post

Are you looking to leverage the advantages of Exosome application, from discovery, to manufacturing, to commercialization? Then look no further than Exosomes Europe, the go-to event for anyone looking to advance their EV research. 📍 DoubleTree Tower of London 💻 Sessions available digitally 📅 5-6 of June 💲 Buy Two Passes, Get One Free* 🌐 Book Now: https://bit.ly/49xSPGV Hear from Founder & CEO of Mursla Bio, Pierre Arsène as he discusses the quest for the 'killer application' of EV products, and answers all your burning questions such as:   🔻 Why hasn't the first 'Killer Application' in EV modality emerged yet? 🔻 What could be missing on the path towards that? 🔻 Which applications are leading the way in Therapeutics, Diagnostics and beyond. 🔻 What are the future perspectives and emerging directions in the EV space? PLUS, we'll help you on the path to exosome success, with in-depth case studies and innovative new data on using EVs for regenerative medicine, skin rejuvenation, cancer treatments, cell-specific cargo delivery & vaccines, genetic therapies, spinal cord injuries, orthopedics and more!   You're spoilt for choice, so book now & don't miss out on hearing direct from those on the front lines of exosome research! PLUS, we're now offering buy two get one free*, so you can upscale the whole team for less! Learn More: https://bit.ly/3T8Pwif *T&Cs on website #Exosomes #ExosomesEurope #ApplicationsOfExosomes #extracellularvesicles #biopharma #pharma #bioprocessing #bioprocess #bioprocessinternational #hybrid #hybridevent #informa #informaconnect

Congratulations to convEyXO on being the latest addition to the "Global Database of Exosome Companies, 2024": https://lnkd.in/ezHg2Pc ConvEyXO, a Belgian biotech company, targets inflammatory and degenerative diseases with unmet medical needs by reducing inflammation and repairing tissue damages from cellular senescence with its Therapeutic Platform based on small Extracellular Vesicles (sEV or exosomes) secreted by Mesenchymal Stem Cells (MSCs), with their intrinsic immuno-modulatory and regenerative properties, amplified by loaded miRNA. ConvEyXO resolves sEV industrialization key challenges with a proprietary Technology Platform, making their therapies triple A with (1) homogenous industrial manufacturing from single cell line sourcing, with robust isolation, purification and characterization processes, (2) cost-efficient scalable production with patented process and proprietary 3D custom fixed-bed bioreactor and (3) Amplified sEV native properties by loading miRNA with a breakthrough microfluidic technology. #exosomes #extracellularvesicles #advancedtherapies Frédéric Tonglet

Congratulations to convEyXO on being the latest addition to the "Global Database of Exosome Companies, 2024": https://lnkd.in/g8VVNaHr ConvEyXO, a Belgian biotech company, targets inflammatory and degenerative diseases with unmet medical needs by reducing inflammation and repairing tissue damages from cellular senescence with its Therapeutic Platform based on small Extracellular Vesicles (sEV or exosomes) secreted by Mesenchymal Stem Cells (MSCs), with their intrinsic immuno-modulatory and regenerative properties, amplified by loaded miRNA. ConvEyXO resolves sEV industrialization key challenges with a proprietary Technology Platform, making their therapies triple A with (1) homogenous industrial manufacturing from single cell line sourcing, with robust isolation, purification and characterization processes, (2) cost-efficient scalable production with patented process and proprietary 3D custom fixed-bed bioreactor and (3) Amplified sEV native properties by loading miRNA with a breakthrough microfluidic technology. #exosomes #extracellularvesicles #advancedtherapies Frédéric Tonglet

📣 Follow our monthly focus on groundbreaking nanobody-exosome research and enjoy up to 30% off on a wide range of exosome products and customizable solutions 📢 Exciting news! Read our blog post on the revolutionary potential of #exosomes in therapy. Discover how our exosome solutions and #nanobody products are shaping #biomedicalresearch: https://lnkd.in/gcjHA8Za Follow us for more updates! #ExosomeResearch #TherapeuticAdvancements

A research team from POSTECH and UNIST has developed UniMat, a platform for scalable production of high-quality organoids, as detailed in Nature Communications. Organoids, which replicate human organ functions, face challenges in reproducibility and scalability, limiting their use in clinical trials and drug development. UniMat uses a 3D engineered nanofiber membrane to enhance uniformity and nutrient delivery, enabling efficient production of mature organoids. The team successfully created kidney organoids and a polycystic kidney disease model, paving the way for standardized disease modeling and drug evaluation, and advancing organoid-based research and development.

After welcoming over 80 participants to our inaugural PluriCon 2024 event back on Sept 10, 2024, Pluristyx, Inc. is thrilled to announce PluriCon 2024 PostScript: a series of posts sharing insights from our speakers. A common theme was the risk of using an inconsistent iPSC starting material both from the perspective of patient safety as well as in the development of a robust and scalable manufacturing process. Over the next few weeks, Pluristyx will be sharing thoughts from select PluriCon 2024 speakers on developing strategies to de-risk iPSCs as a starting material for regenerative medicine therapies.   💠 Translating Today’s Discoveries into Tomorrow’s Therapies - Observations and experiences in the complexities of translating cell therapies to industry with an emphasis on continuous improvement and optimization of the manufacturing process. 💠 Designing a Better Cell Therapy – Novel technologies for iPSC differentiation to address cost, consistency and scalability challenges. 💠 Testing for Success – Creating robust iPSC lines suitable for clinical applications by developing strategies around improving testing methods and optimizing workflows to identify loss of genetic integrity.    💠 Culture Consistency – Understanding variability in iPSC cell culture to minimize stressors and develop a controlled, reproducible and cost-effective paradigm for iPSC culture and cryopreservation.   💠 Developing an iPSC-based clinical therapy – A case study in overcoming the challenges of developing an iPSC-based therapy including conducting extensive genomic analysis to ensure safety, freedom to operate and IP considerations. 💠 Regulatory Challenges and Opportunities – Insights into the regulatory landscape for iPSC-based therapies centered around the risk-reward calculus of regulatory expectations vs. risk management.   💠 Cryopreservation Considerations for iPSC-derived products – An often under appreciated and overlooked step in the manufacturing process, cryopreservation is often a hidden hurdle towards commercialization.    We hope that these posts will spark discussions between regulators, therapy developers, and academics on existing challenges in using iPSCs for clinical development.  Stay up to date as we release weekly deep dives into these critical topics to continue the conversation in developing Tomorrow’s Cell Therapies, Today®: https://lnkd.in/g99f-vE6     #PluriCon2024 #StemCells #Celltherapy #iPSC

𝐂𝐚𝐫𝐝𝐢𝐚𝐜 𝐓𝐢𝐬𝐬𝐮𝐞 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐒𝐞𝐭 𝐟𝐨𝐫 𝐑𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 𝐆𝐫𝐨𝐰𝐭𝐡 Download PDF Brochure: https://lnkd.in/dSjg8ACc Exciting developments in the cardiac tissue engineering market reveal promising trajectories! New market analysis shows the sector valued at $621.2M in 2024 is poised to reach $1.33B by 2029, demonstrating a robust CAGR of 16.5%. Key Growth Drivers: • Expanding demand for regenerative medicine solutions • Rising cardiovascular disease incidents globally • Breakthrough developments in stem cell research Market Segments: • Materials: Advanced scaffolds and stem cell technologies • Products: Heart valves and vascular grafts • Applications: Myocardial infarction and congenital heart disease • End-Users: Leading hospitals, clinics, and research institutions 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Terumo Medical Corporation, Artivion, Inc., Baxter International Inc., Teijin Limited, Medtronic, Boston Scientific, Abbott, Merck KGaA, Darmstadt, Germany, Elutia, W. L. Gore & Associates, Meril, FUJIFILM Holdings Corporation, Vascudyne Inc, BICO, REPROCELL, PromoCell, Axol Bioscience Ltd., BPS Bioscience Inc., Cell Application, Inc. (US), Viscofan DE GmbH #HealthcareInnovation #BiotechMarket #CardiacCare #RegenerativeMedicine #MarketResearch #MedTech #Healthcare #Innovation #BioTechnology

𝐋𝐈𝐅𝐓𝐎𝐒𝐂𝐎𝐏𝐄: 𝐀𝐈-𝐜𝐨𝐧𝐭𝐫𝐨𝐥𝐥𝐞𝐝, 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 Together with the Fraunhofer-Institut für Produktionstechnologie IPT, the Fraunhofer ILT has developed a new AI-supported high-throughput process for fully automated cell selection. The LIFTOSCOPE localizes, identifies and measures dozens of living cells per second and transfers them to microtiter plates using laser-induced forward transfer (LIFT). This technology opens up significant advances in personalized medicine, pharmaceutical and clinical research. The innovative process not only enables the efficient isolation of pluripotent stem cells, but also high-producer and immune cells. The use of AI and lasers in this fully automated process promises maximum throughput and survival rates of over 90 percent. Learn more about this exciting technology in our video. #CellTherapy #Innovation #Fraunhofer #LIFTOSCOPE #fraunhoferilt #biofacbrication #medicaltechnology #personalizedmedicine #FutureofMedicine #lasertechnology #photonics #photonicsinaachen 

As exosomes emerge as vital biomarkers and delivery systems in personalized medicine, Malvern Panalytical remains committed to advancing this field through collaboration with leading companies and CROs. Together, we can tackle the challenges of exosome isolation and characterization, paving the way for groundbreaking discoveries. -Exosome Isolation and Characterization Technologies -Applications in Drug Delivery -Biomarker Discovery and Diagnostics -Regulatory Compliance and Standardization -Collaboration and Partnership Opportunities Read more about the exosome market dynamics here: [Global Exosome Market Insights](https://lnkd.in/ev8QTzNe) #ExosomeResearch #PersonalizedMedicine #MalvernPanalytical #Biotechnology #Collaboration

Preclinical Imaging Market: A Global Perspective 🌐 📥 Download Complete PDF: https://lnkd.in/dtjxaqZa The preclinical imaging market is expected to grow significantly, reaching an estimated USD 5,101 million by 2029 from USD 3,997 million in 2024, with a CAGR of 5.0%. 📈 This growth is driven by advancements across product types like Optical Imaging (Bioluminescence), PET, SPECT, and MRI—technologies essential in early-stage drug discovery and research. In addition, innovations in optical imaging reagents (e.g., infrared dyes) and specialized software are enhancing research capabilities, supporting new breakthroughs in both oncology and neurology. Key stakeholders such as pharmaceutical companies and imaging centers are increasingly investing in these tools to accelerate the development of new therapeutics. 🌍 The market growth is anticipated globally, with notable regional expansions as demand for precision medicine and tailored treatments rises. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Bruker Bruker BioSpin Revvity MR SOLUTIONS Mediso Medical Imaging Systems TriFoil Imaging FUJIFILM VisualSonics, Inc. MILabs Aspect Imaging LI-COR BIOSCIENCES UK LIMITED ICONEUS ADVANCED MOLECULAR VISION LIMITED IVIM Technology Cubresa Inc. Berthold Technologies SOFIE Medlink Imaging, a Vieworks Company AI4R KUBTEC Medical Imaging MEDIKORS INC. Miltenyi Biotec #PreclinicalImaging #HealthcareInnovation #DrugDevelopment #Oncology #Neurology #GlobalMarket #ImagingSolutions #Pharma